Tibial Bypass in Patients with Intermittent Claudication Is Associated with Poor Outcomes.

[1]  D. Rybin,et al.  Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss. , 2019, Journal of vascular surgery.

[2]  D. Rybin,et al.  Broad variation in prosthetic conduit use for femoral-popliteal bypass is not justified on the basis of contemporary outcomes favoring autologous great saphenous vein. , 2019, Journal of vascular surgery.

[3]  A. Presson,et al.  Optimal medical management before lower extremity bypass for claudication in the veteran population , 2019, Journal of vascular surgery.

[4]  L. Wann,et al.  ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and So , 2019, Journal of the American College of Cardiology.

[5]  R. Hawkins,et al.  Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication , 2018, Journal of vascular surgery.

[6]  M. Schermerhorn,et al.  Active smoking in claudicants undergoing lower extremity bypass predicts decreased graft patency and worse overall survival , 2018, Journal of vascular surgery.

[7]  Daniel J. Luckett,et al.  The impact of current smoking on outcomes after infrainguinal bypass for claudication , 2018, Journal of vascular surgery.

[8]  P. Wilson,et al.  High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization , 2018, Journal of Vascular Surgery.

[9]  L. Norgren,et al.  A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. , 2017, Circulation.

[10]  A. Kodama,et al.  Raison d'etre of Tibial Artery Bypass for Intermittent Claudication in the Era of Endovascular Therapy. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[11]  A. Beck,et al.  Using the Vascular Quality Initiative to improve quality of care and patient outcomes for vascular surgery patients. , 2015, Seminars in vascular surgery.

[12]  M Hassan Murad,et al.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.

[13]  A. Meltzer,et al.  Defining risks and predicting adverse events after lower extremity bypass for critical limb ischemia , 2014, Vascular health and risk management.

[14]  A. Meltzer,et al.  Assessing the Perioperative Safety of Common Femoral Endarterectomy in the Endovascular Era , 2014, Vascular and endovascular surgery.

[15]  M. Davies,et al.  Regional quality groups in the Society for Vascular Surgery® Vascular Quality Initiative. , 2013, Journal of vascular surgery.

[16]  April E. Nedeau,et al.  Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. , 2012, Journal of vascular surgery.

[17]  C. Kalbaugh,et al.  Do current outcomes justify more liberal use of revascularization for vasculogenic claudication? A single center experience of 1,000 consecutively treated limbs. , 2008, Journal of the American College of Surgeons.

[18]  C. Soong,et al.  Benefits of a Supervised Exercise Program After Lower Limb Bypass Surgery , 2007, Vascular and endovascular surgery.

[19]  M. Eneroth Factors affecting wound healing after major amputation for vascular disease: A review , 1999, Prosthetics and orthotics international.

[20]  M. Donaldson,et al.  Femorotibial bypass for claudication: do results justify an aggressive approach? , 1995, Journal of vascular surgery.